Milestone Pharmaceuticals announces FDA acceptance of the company’s response to the CRL for Cardamyst (etripamil) nasal spray

Milestone Pharmaceuticals

11 July 2025 - New PDUFA action date of 13 December 2025.

Milestone Pharmaceuticals today announced that the US FDA has accepted for review Milestone’s response to issues raised in the complete response letter for Cardamyst (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia.

Read Milestone Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier , Registration